Literature DB >> 10685762

The cost of hospitalization in Crohn's disease.

R D Cohen1, L R Larson, J M Roth, R V Becker, L L Mummert.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the demographics, resource use, and costs associated with hospitalization of Crohn's disease patients.
METHODS: All patients hospitalized at our institution from 7/1/96 to 6/30/97 with a primary diagnosis of "Crohn's Disease" were analyzed using a computerized database. Data are presented "per hospitalization."
RESULTS: A total of 175 hospitalizations (147 patients) were identified. Mean patient age was 36.5 yr; 61% were female; 82% Caucasian. Payer mix was most commonly contracted (57%), commercial (21%), or Medicare (13%). 57% of hospitalizations had a primary surgical procedure; the remainder were medical. Average length of stay was 8.7 days (surgical, 9.6 days; medical, 7.5 days). The average cost of hospitalization, excluding physician fees, was $12,528 (surgical, $14,409; medical, $10,020), whereas average charges were $35,378 (surgical, $46,354; medical, $20,744), including physician fees, which averaged $7,249 (surgical, $11,217; medical, $1,959). Mean reimbursements were $21,968 (surgical, $28,946; medical, $12,666) with average weighted reimbursement rates of 60.17% of hospital charges, 69.57% of physician fees. The distribution of costs across subcategories was: Surgery (39.6%), Pharmacy (18.6%), Laboratory (3.8%), Radiology (2.1%), Pathology (0.8%), Endoscopy (0.3%), and Other Hospital Costs (34.9%). Of the hospitalizations, 87% included treatment with steroids, 23% with immunomodulators, and 14% with aminosalicylates; 27% included the administration of total parenteral nutrition, which accounted for 63% of the total pharmacy costs.
CONCLUSIONS: Surgery accounts for the majority of hospitalizations, nearly 40% of their total costs, and 75% of overall charges and reimbursements. Therapy that decreases the number of surgical hospitalizations should substantially reduce inpatient Crohn's disease costs, as well as overall costs.

Entities:  

Mesh:

Year:  2000        PMID: 10685762     DOI: 10.1111/j.1572-0241.2000.01779.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  42 in total

Review 1.  Crohn's disease: a clinical update.

Authors:  Francis Ha; Hanan Khalil
Journal:  Therap Adv Gastroenterol       Date:  2015-11       Impact factor: 4.409

Review 2.  Economic implications of biological therapies for Crohn's disease: review of infliximab.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

Authors:  Andrew P Yu; Scott Johnson; Si-Tien Wang; Pavel Atanasov; Jackson Tang; Eric Wu; Jingdong Chao; Parvez M Mulani
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Complex home care: Part I--Utilization and costs to families for health care services each year.

Authors:  Ubolrat Piamjariyakul; Vicki M Ross; Donna Macan Yadrich; Arthur R Williams; Lyn Howard; Carol E Smith
Journal:  Nurs Econ       Date:  2010 Jul-Aug       Impact factor: 1.085

Review 5.  The pharmacoeconomics of biologic therapy for IBD.

Authors:  Russell D Cohen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-02       Impact factor: 46.802

6.  Funding a smoking cessation program for Crohn's disease: an economic evaluation.

Authors:  Stephanie Coward; Steven J Heitman; Fiona Clement; Maria Negron; Remo Panaccione; Subrata Ghosh; Herman W Barkema; Cynthia Seow; Yvette P Y Leung; Gilaad G Kaplan
Journal:  Am J Gastroenterol       Date:  2014-10-28       Impact factor: 10.864

Review 7.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  Hematopoietic cell transplantation for Crohn's disease; is it time?

Authors:  Y Leung; M Geddes; J Storek; R Panaccione; P L Beck
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

9.  Intestinal surgery for Crohn's disease: predictors of recovery, quality of life, and costs.

Authors:  Marco Scarpa; Cesare Ruffolo; Domenico Bassi; Riccardo Boetto; Renata D'Incà; Andrea Buda; Giacomo C Sturniolo; Imerio Angriman
Journal:  J Gastrointest Surg       Date:  2009-09-25       Impact factor: 3.452

10.  Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease.

Authors:  Benjamin Click; Claudia Ramos Rivers; Ioannis E Koutroubakis; Dmitriy Babichenko; Alyce M Anderson; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Leonard Baidoo; Arthur Barrie; Miguel Regueiro; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2016-06       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.